SYMBOL:

    Up to 100 tickers separated by a space .....Watch Pre-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
SANGAMO BIOSCIENCES
(NQNM:SGMO Last Sale: 8.38 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (SGMO : $8.38)
$973,851 million Market Cap at Market Close, July 1, 2022
Employs 55.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
501 Canal Blvd Research Report Earnings Snapshot - Last 10/22/18
Suite A100 Fact Sheet
Richmond, CA 94804 Financial Statements
Phone: (510) 970-6000 Peer Comparison
Fax: (510) 236-8951 Annual Reports

Edward O. Lanphier II, Pres./CEO, Gregory S. Zante, CFO
Develops zinc finger DNA-binding proteins (ZFPs) that control gene expression and cell function. Markets to the drug discovery, agricultural, and biotechnology industries. IPO at $15 April 5, 2000. Raised $52.5 million, selling 3.5 million shares, 17% of the outstanding. Lead Manager: Lehman Brothers. Reported positive pre-clinical animal data for its ZFP Therapeutic SB-509 for the treatment of diabetic neuropathy, May 30, 2006.
Historical Charts    Technical Analysis
No Historical Data available for SGMO

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common SGMO $8.38 $8.38 0 .0 $7.74 $8.39 1,454,361 $7.74 $8.39 116,211,355
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $973,851,155

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex